Opexa Therapeutics, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 1,267 - - -
Cost of Revenue - - - -
Gross Profit 1,267 - - -
Operating Expenses
Research and Development 9,181 6,318 3,340 2,585
Sales, General and Admin. 3,671 2,509 2,406 2,216
Non-Recurring Items - - - -
Other 336 304 210 169
Operating Income (11,923) (9,134) (5,966) (4,970)
Income From Continuing Operations
Add'l Income/Expense Items (2,468) 550 (9) 1
Earnings Before Interest and Tax (11,872) (8,584) (5,975) (4,969)
Interest Expense 2,267 350 3 501
Earnings Before Tax (14,140) (8,934) (5,978) (5,470)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (16,658) (8,934) (5,978) (5,470)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (16,656) (8,931) (5,968) (5,469)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (16,656) (8,931) (5,968) (5,469)